Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

NCT03237377 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped low accrual

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
RADIATION: Thoracic Radiation
PROCEDURE: lobectomy
DRUG: Standard of care adjuvant chemotherapy

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]